Magnolia Capital Advisors LLC Buys Shares of 6,911 Edwards Lifesciences Co. (NYSE:EW)

Magnolia Capital Advisors LLC bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 6,911 shares of the medical research company’s stock, valued at approximately $511,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Martin Capital Advisors LLP raised its stake in Edwards Lifesciences by 0.5% in the fourth quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock worth $1,944,000 after buying an additional 128 shares in the last quarter. Legacy Wealth Asset Management LLC increased its stake in shares of Edwards Lifesciences by 0.8% during the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after purchasing an additional 134 shares in the last quarter. DMC Group LLC increased its stake in shares of Edwards Lifesciences by 4.5% during the fourth quarter. DMC Group LLC now owns 3,561 shares of the medical research company’s stock valued at $272,000 after purchasing an additional 154 shares in the last quarter. Granite Harbor Advisors Inc. increased its stake in shares of Edwards Lifesciences by 4.2% during the third quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company’s stock valued at $265,000 after purchasing an additional 155 shares in the last quarter. Finally, Stableford Capital II LLC increased its stake in shares of Edwards Lifesciences by 2.7% during the fourth quarter. Stableford Capital II LLC now owns 5,980 shares of the medical research company’s stock valued at $449,000 after purchasing an additional 155 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In other news, VP Daniel J. Lippis sold 1,715 shares of the firm’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $90.98, for a total transaction of $156,030.70. Following the sale, the vice president now directly owns 17,213 shares in the company, valued at approximately $1,566,038.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of Edwards Lifesciences stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $90.98, for a total value of $156,030.70. Following the sale, the vice president now directly owns 17,213 shares in the company, valued at approximately $1,566,038.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock worth $17,166,254 in the last three months. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Stock Performance

EW stock traded up $0.87 on Wednesday, hitting $88.62. The company had a trading volume of 3,234,911 shares, compared to its average volume of 3,823,988. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The stock’s 50-day simple moving average is $90.23 and its 200 day simple moving average is $78.69. The stock has a market cap of $53.34 billion, a price-to-earnings ratio of 38.53, a P/E/G ratio of 4.31 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting the consensus estimate of $0.64. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company’s revenue was up 13.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.64 EPS. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on EW shares. Evercore ISI raised their target price on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Oppenheimer raised their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Royal Bank of Canada raised their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Finally, OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.73.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.